Menopause and the Menopausal Transition

Medical Clinics of North America

Volumn 92, Issue 5, 2008, Pages 1253-1271

  Lund, Kirsten J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DROSPIRENONE PLUS ESTRADIOL; ELESTRIN; ESCLIM; ESTRADIOL; ESTRADIOL ACETATE; ETHINYLESTRADIOL; ETIDRONIC ACID; FLUOXETINE; GABAPENTIN; GESTAGEN; IBANDRONIC ACID; LEUPRORELIN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHISTERONE ACETATE; NORGESTIMATE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PAROXETINE; PIPERAZINE ESTRONE SULFATE; PREFEST; PROGESTERONE; RALOXIFENE; RECLAST; RISEDRONIC ACID; SALCATONIN; SEROTONIN UPTAKE INHIBITOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZOLEDRONIC ACID;

BLEEDING; BREAST CANCER; CANCER SCREENING; CORONARY ARTERY DISEASE; FRAGILITY FRACTURE; HEALTH CARE MANAGEMENT; HEALTH EDUCATION; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE AND CLIMACTERIUM; MENSTRUAL CYCLE; MENSTRUATION DISORDER; OSTEOPOROSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCREENING TEST; URINE INCONTINENCE; VASCULAR DISEASE; VASOMOTOR DISORDER;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; NEOPLASMS; OSTEOPOROSIS, POSTMENOPAUSAL; PERIMENOPAUSE; QUALITY OF LIFE;

EID: 49449094462     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.04.009     Document Type: Review

References (69)

1. Soules M.R., Sherman S., Parrott E., et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 76 5 (2001) 874-878
2. Morabia A., and Costanza M.C. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 148 12 (1998) 1195-1205
3. Meschia M., Pansini F., Modena A.B., et al. Determinants of age at menopause in Italy: results from a large cross-sectional study. ICARUS Study Group. Italian Climacteric Research Group Study. Maturitas 34 2 (2000) 119-125
4. Parazzini F. Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas 56 3 (2007) 280-287
5. Nagel G., Altenburg H.P., Nieters A., et al. Reproductive and dietary determinants of the age at menopause in EPIC-Heidelberg. Maturitas 52 3-4 (2005) 337-347
6. Farquhar C. The association of hysterectomy and menopause: a prospective cohort study. BJOG 112 7 (2005) 956-962
7. Hardy R., and Kuh D. Reproductive characteristics and the age at inception of the perimenopause in a British National Cohort. Am J Epidemiol 149 7 (1999) 612-620
8. MacNaughton J., Banah M., McCloud P., et al. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol (Oxf) 36 4 (1992) 339-345
9. Santoro N., Brown J.R., Adel T., et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 81 4 (1996) 1495-1501
10. Minino A. Deaths: final data for 2004 (2007), National Center for Health Statistics, Hyattsville (MD)
11. American Heart Association. Heart disease and stroke statistics-2008 update (2008), American Heart Association, Dallas (TX)
12. Collins P., Rosano G., Casey C., et al. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. Climacteric 10 6 (2007) 508-526
13. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 10 (2004) 1245-1250
14. Mosca L. Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 10 4 Suppl 3 (2007) 19-25
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 7329 (2002) 71-86
16. Cook N.R., Lee I.M., Gaziano J.M., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 1 (2005) 47-55
17. Johnell O. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17 12 (2006) 1726-1733
18. Pasco J.A., Seeman E., Henry M.J., et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 17 9 (2006) 1404-1409
19. Flicker L., Hopper J.L., Rodgers L., et al. Bone density determinants in elderly women: a twin study. J Bone Miner Res 10 11 (1995) 1607-1613
20. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 21 1 (2007) 109-122
21. Weatherall M. Prevention of falls and fall-related fractures in community-dwelling older adults: a meta-analysis of estimates of effectiveness based on recent guidelines. Intern Med J 34 3 (2004) 102-108
22. Torgerson D.J., and Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285 22 (2001) 2891-2897
23. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 7 (1999) 637-645
24. Siris E.S., Harris S.T., Eastell R., et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20 9 (2005) 1514-1524
25. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85 11 (2000) 4118-4124
26. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004 Incidence and Mortality Web-based Report. 2007. Available at: www.cdc.gov/uscs. Accessed January 30, 2008.
27. CDC. Lung cancer risk factors. Available at: http://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm. Accessed June 23, 2008.
28. Wakelee H.A., Chang E.T., Gomez S.L., et al. Lung cancer incidence in never smokers. J Clin Oncol 25 5 (2007) 472-478
29. Reeves G.K., Pirie K., Beral V., et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335 7630 (2007) 1134
30. Smith-Warner S.A., Spiegelman D., Yaun S.S., et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 279 7 (1998) 535-540
31. Gotzsche P.C., and Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 18 4 (2006) CD001877
32. Samad A.K., Taylor R.S., Marshall T., et al. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis 7 3 (2005) 204-213
33. Park Y., Hunter D.J., Spiegelman D., et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 294 22 (2005) 2849-2857
34. Geiger T.M., Miedema B.W., Geana M.V., et al. Improving rates for screening colonoscopy: analysis of the health information national trends survey (HINTS I) data. Surg Endosc 22 2 (2008) 527-533
35. Whiteman M.K., Hillis S.D., Jamieson D.J., et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 198 1 (2008) 34 e31-7
36. Trimble C.L., Kauderer J., Zaino R., et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106 4 (2006) 812-819
37. Parker W.H. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 87 4 (2007) 725-736
38. Scialli A.R., and Jestila K.J. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril 64 2 (1995) 313-320
39. Fiscella K., Eisinger S.H., Meldrum S., et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 108 6 (2006) 1381-1387
40. Freeman E.W., and Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 10 3 (2007) 197-214
41. Hammar M., Berg G., and Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes?. Acta Obstet Gynecol Scand 69 5 (1990) 409-412
42. Thurston R.C., Joffe H., Soares C.N., et al. Physical activity and risk of vasomotor symptoms in women with and without a history of depression: results from the Harvard Study of Moods and Cycles. Menopause 13 4 (2006) 553-560
43. MacLennan A., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 4 1 (2001) 58-74
44. Lethaby A.E., Brown J., Marjoribanks J., et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 17 4 (2007) CD001395
45. Guttuso Jr. T., Kurlan R., McDermott M.P., et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 101 2 (2003) 337-345
46. Evans M.L., Pritts E., Vittinghoff E., et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 105 1 (2005) 161-166
47. Reddy S.Y., Warner H., Guttuso Jr. T., et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 108 1 (2006) 41-48
48. Suvanto-Luukkonen E., Koivunen R., Sundstrom H., et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 12 1 (2005) 18-26
49. Stearns V., Slack R., Greep N., et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 23 28 (2005) 6919-6930
50. Gordon P.R., Kerwin J.P., Boesen K.G., et al. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 13 4 (2006) 568-575
51. Pandya K.J., Raubertas R.F., Flynn P.J., et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132 10 (2000) 788-793
52. Chiechi L.M., Putignano G., Guerra V., et al. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. Maturitas 45 4 (2003) 241-246
53. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 14 3 Pt 1 (2007) 355-369 quiz 370-351
54. Nilsson K., Risberg B., and Heimer G. The vaginal epithelium in the postmenopause-cytology, histology and pH as methods of assessment. Maturitas 21 1 (1995) 51-56
55. Suckling J., Lethaby A., and Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 18 4 (2006) CD001500
56. Hannestad Y.S., Rortveit G., Sandvik H., et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 53 11 (2000) 1150-1157
57. Danforth K.N., Townsend M.K., Lifford K., et al. Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol 194 2 (2006) 339-345
58. Hay-Smith E.J., and Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 25 1 (2006) CD005654
59. Ghoniem G.M., Van Leeuwen J.S., Elser D.M., et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173 5 (2005) 1647-1653
60. Lapitan M.C., Cody D.J., and Grant A.M. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 1 1 (2003) CD002912
61. Nabi G., Cody J.D., Ellis G., et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 18 4 (2006) CD003781
62. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335 7 (1996) 453-461
63. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20 1 (1991) 47-63
64. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273 3 (1995) 199-208
65. Clarkson T.B. Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. Fertil Steril 62 6 Suppl 2 (1994) 147S-151S
66. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
67. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 14 (2004) 1701-1712
68. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19 1 (1998) 61-109
69. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 356 25 (2007) 2591-2602